With $14 Billion Purchase Pfizer Signals That Cancer Drug Prices Will Remain High
Aug 22, 2016, 13:20 PM
by
Michael Croft
Forbes | Pfizer says it will purchase biotechnology upstart Medivation for $14 billion in cash. The main prize in the deal: Medivation's prostate cancer drug, Xtandi, which costs $120,000 a year.
August 22, 2016 | Pfizer says it will purchase biotechnology upstart Medivation for $14 billion in cash. The main prize in the deal: Medivation's prostate cancer drug, Xtandi, which costs $120,000 a year. Forbes